KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Equity Average (2016 - 2025)

Eli Lilly's Equity Average history spans 17 years, with the latest figure at $25.2 billion for Q4 2025.

  • For Q4 2025, Equity Average rose 246.22% year-over-year to $25.2 billion; the TTM value through Dec 2025 reached $25.2 billion, up 246.22%, while the annual FY2025 figure was $20.4 billion, 89.61% up from the prior year.
  • Equity Average reached $25.2 billion in Q4 2025 per LLY's latest filing, up from $11.0 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $25.2 billion in Q4 2025 to a low of -$3.4 billion in Q1 2023.
  • Average Equity Average over 5 years is $3.1 billion, with a median of $1.1 billion recorded in 2021.
  • The largest YoY upside for Equity Average was 3879.68% in 2025 against a maximum downside of 1056.32% in 2025.
  • A 5-year view of Equity Average shows it stood at $386.9 million in 2021, then tumbled by 412.6% to -$1.2 billion in 2022, then skyrocketed by 410.89% to $3.8 billion in 2023, then surged by 93.3% to $7.3 billion in 2024, then surged by 246.22% to $25.2 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Equity Average are $25.2 billion (Q4 2025), $11.0 billion (Q3 2025), and -$1.8 billion (Q2 2025).